Orphan accelerator creating non-profit model to commercialize ultrarare therapies

The Orphan Therapeutics Accelerator, a non-profit biotech that is creating new business models to bring therapies to patients with ultrarare diseases, announced Wednesday that two biopharma companies have joined as founding members, and it has entered into partnership with contract manufacturing and research organizations.

The accelerator, also known as OTXL, was launched in 2024 in response to an all-too-common scenario. ...